Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-4225-7
Abstract: Treatment options for recurrent glioblastoma multiforme (GBM) are very limited. GBM cells express high levels of the GPCR neurokinin type 1 receptor (NK-1R), and a modified substance P can be used as its ligand for… read more here.
Keywords: therapy; dota substance; dota; targeted alpha ... See more keywords